Trial: 202001014

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia



Principal Investigator

Ghobadi, Armin

Disease Site

Chronic Lymphocytic Leukemia (CLL); Lymphoid Leukemia; Non-Hodgkin’s Lymphoma

Learn more about this study at: